Description

Dapagliflozin Tablets 10?mg (Hetangjing) offer a research-grade sodium-glucose co-transporter 2 (SGLT2) inhibition model in laboratory settings. Each box contains 30 tablets of 10?mg, produced by Yiling Wanzhou International Pharmaceutical (approval #H20234636). This product supports controlled studies on renal glucose excretion, glycemic control, and cardiorenal mechanisms.

As an SGLT2 inhibitor, Dapagliflozin blocks renal glucose reabsorption, promoting glucosuria. It has also shown benefits in reducing heart failure hospitalization and chronic kidney disease progression.

Note: This product is strictly for laboratory or experimental research. Not for human or veterinary use.

Product Parameters

Mechanism & Research Applications

Dapagliflozin is a selective SGLT2 inhibitor that induces urinary glucose excretion by blocking glucose reabsorption in the renal proximal tubule. In research contexts, it is used to model:

• Glucose-lowering effects in Type 2 diabetes

• Renal glucose handling and osmotic diuresis

• Preclinical kidney and heart failure protection mechanisms

• Combination therapy with metformin or GLP?1 analogs

Its well-studied mechanism in glucose and kidney research makes it a reliable tool compound.

Safety & Handling

• For research use only—not approved for clinical or therapeutic applications

• Handle with appropriate lab safety protocols

• Dispose of unused tablets according to chemical waste guidelines

Research Use Disclaimer

This product is exclusively for laboratory or research purposes. It is not intended for clinical, diagnostic, or therapeutic use in humans or animals. Please follow all applicable regulations and institutional guidelines.